GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Cepheid to Develop Cervical Cancer Test with HPV Technology from Quantovir

  • Cepheid will exclusively license Quantovir’s HPV patent portfolio to develop a diagnostic for cervical cancer. Quantovir has reportedly demonstrated that a molecular test measuring the viral load of HPV DNA present in cervical specimens can be used to predict a woman’s risk of developing cervical cancer.

    Cepheid plans to develop a quantitative measurement of high-risk HPV types for the GeneXpert® System. The test is expected to provide accurate PCR results in minutes rather than days in a variety of clinical settings, according to John L. Bishop, CEO of Cepheid.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Value-Pricing Cancer Drugs

Do you think all new cancer drugs awaiting approval should undergo value-pricing?

More »